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Abstract
Background: The implementation project of the national diabetes prevention programme in Finland, FIN-D2D, was
carried out in primary health care in the area of five hospital districts during 2003-2007.
Methods: The population strategy of FIN-D2D was primarily aimed at increasing the awareness of type 2 diabetes
and preventing obesity. To investigate the effects of this strategy, we studied the changes in the prevalence of
obesity, overweight, and central obesity among a random independent sample of individuals aged 45-74 years in the
FIN-D2D area; and assessed whether they differed from a sample of individuals in the control area, which consisted
of four geographical areas not participating in FIN-D2D (FINRISK study). Data was obtained for 5850/ 6406 (in the
beginning/ in the end) individuals. The duration of the observation period varied from three to five years.
Results: The mean body weight decreased from 78.7 to 78.1 kg (p=0.041) in the FIN-D2D area, and from 78.7 to
78.0 kg (p=NS) in the control area. The prevalence of obesity (BMI ≥30 kg/m
2) decreased in the FIN-D2D area
(26.5% vs. 24.4%, p=0.015), and in the control area (28.4% vs. 25.2%, p=0.005). The prevalence of morbid obesity
(BMI ≥40 kg/m
2) remained unchanged in the FIN-D2D area, but increased in the control area (1.2% vs. 2.3%, p=
0.007). The mean waist circumference remained unchanged in the FIN-D2D area, but increased in the control area
(92.8 vs. 94.0 cm, p=0.005).
Conclusions: The prevalence of obesity may be decreasing among 45-74 year old Finns. We still need a longer
time perspective and future studies to see whether this favourable trend can be sustained in Finland. The actions
of this implementation project can at least partly explain the differences in the mean waist circumference and the
prevalence of morbid obesity between the intervention and control areas.
Background
During the last decades, the prevalence of obesity has
doubled in adults in the United States [1] and in Finland
[2]. However, recent reports have shown that the obesity
epidemic might be slowing down [3,4]. Obesity is
strongly associated with a reduction in life expectancy, as
well as with an increased risk of type 2 diabetes (T2DM),
coronary heart disease, and certain cancers [5]. Further-
more, obesity increases the risk of musculoskeletal
disorders [6] and early retirement [7]. Obesity increases
the risk of T2DM to a much greater extent than it
increases the risk of other diseases, independently of age,
race, and physical activity [8]. Furthermore, numerous
large-scale studies have shown that overall mortality rises
steadily as a function of increasing body weight [9], and
even small increases in weight across a population can
have a devastating impact on public health.
According to a large meta-analysis, more than a half of
the Europeans will suffer from hyperglycemia and T2DM
during their lifetime [10,11]. Thus, the economic burden
is already big and will be huge in the forthcoming years
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reproduction in any medium, provided the original work is properly cited.[12]. The most efficient way to manage T2DM and its
complications is to prevent the onset of diabetes and pre-
diabetic states. As several intervention trials have demon-
strated, prevention of T2DM and its complications is
possible and efficient by modest changes in lifestyle, pri-
marily in diet and physical activity [13-17]. Moreover, it
has been shown that the achieved benefit from lifestyle
interventions can be sustained for years after the active
period [18-20]. A recent meta-analysis [21] has shown
that lifestyle interventions for patients at high risk of dia-
betes, delivered by a variety of healthcare providers in
routine clinical settings, are feasible but appear to be of
limited clinical benefit one year after intervention.
Although weight and waist circumference reductions
were achieved, translation into routine practice had less
effect on diabetes risk reduction [21].
To translate the scientific evidence regarding preven-
tion of T2DM into daily practice and public health, the
first large-scale national type 2 diabetes prevention pro-
gramme was carried out in Finland, covering three con-
current strategies: the population strategy, the high-risk
strategy, and the strategy of early diagnosis and treatment
[22,23]. The baseline results of the implementation pro-
ject, FIN-D2D, have shown that only 58% of men and
67% of women have normal glucose tolerance, and the
disturbances of glucose metabolism are closely associated
with obesity and central obesity [24]. FIN-D2D supported
the population strategy that aimed to improve the health
of the entire population through a healthy diet and regu-
lar physical activity [22]. Different manners, such as
media communication, training, lifestyle counselling and
an extensive network supporting these activities, were
used to prevent obesity, metabolic syndrome and other
risk factors of T2DM [25]. The project was carried out in
five hospital districts in Finland in 2003-2007.
In this study based on two independent surveys with a
follow-up of 3 to 5 years, we examined the effects of FIN-
D2D on the prevalence of obesity, overweight, and cen-
tral obesity at the population-level, among 45-74 years
old Finnish men and women, and assessed whether these
effects differ from the respective changes among Finnish
population living in four geographical areas not partici-
pating in FIN-D2D. The results of this study reflect the
achievements of all three concurrent strategies at the
population-level, whereas the 1-year results of the high-
risk strategy have been published elsewhere [26].
Methods
FIN-D2D was carried out in five hospital districts, cover-
ing altogether 1.5 million people (South Ostrobothnia,
Central Finland, Pirkanmaa, Northern Ostrobothnia, and
Northern Savo) during 2003-2007. As a part of the eva-
luation, population-based health examination surveys
with independent random samples from the population
were conducted in the beginning and at the end of the
project period. Individuals aged 45-74 years, stratified
according to sex, 10-year age groups (45-54, 55-64, and
65-74 years) and five geographical areas, were selected
from the National Population Register at the beginning
of the project (year 2002 for Northern Ostrobothnia and
Northern Savo, and year 2004 for South Ostrobothnia,
Central Finland, and Pirkanmaa) and at the end of the
project (year 2007 for all five areas). Data on anthropo-
metric measurements were obtained for 3812 and 4156
individuals (at the beginning and at the end, respectively).
The FINRISK study [27,28] is a chronic disease risk fac-
tor survey of the middle-aged Finnish population that has
been carried out every five years since 1972. The geogra-
phical FINRISK study areas which were not participating
in FIN-D2D project were used as a control area in this
study (Figure 1). In this study we used the data from
FINRISK-2002 and FINRISK-2007 studies covering the
following geographical areas in Finland: Northern Savo,
Northern Karelia, Northern Ostrobothnia, Kainuu, Turku
and Loimaa region, and the cities of Helsinki and Vantaa.
Northern Savo and Northern Ostrobothnia belong to the
FIN-D2D area (hospital districts of Northern Savo and
Northern Ostrobothnia, respectively), thus the data from
these areas were combined with the FIN-D2D data from
the hospital districts of South Ostrobothnia, Central
Finland, and Pirkanmaa, to constitute the FIN-D2D area
[25]. Study participants aged 45-74 years were included in
this study. Data on anthropometric measurements were
obtained for 2038 and 2250 (years 2002 and 2007, respec-
tively) individuals from the areas of Northern Karelia,
Kainuu, Turku-Loimaa, and Helsinki-Vantaa [25]. This
study population will be referred to as the control area in
this study.
The primary strategy of the FIN-D2D was a high-risk
strategy, the aim of which was to include prevention of
diabetes and reduction of cardiovascular risk factor
levels among high-risk individuals in daily routines in
primary health care centers and occupational health
care outpatient clinics [26]. The population strategy
focused on raising awareness of diabetes and its risk fac-
tors in the overall population, and the early treatment
strategy focused on care of diabetes in individuals who
had screening-detected diabetes [26]. The different stra-
tegies have been described in detail elsewhere [23,26].
Subjects were invited by mail to a clinical examination.
Together with the invitation, they also received a self-
administered questionnaire on socioeconomic back-
ground, medical history, and health behaviour. They
were asked to complete the questionnaire at home, and
bring it with them to the health examination, which was
carried out according to the WHO MONICA project
protocol [29]. At the study site, height, weight and waist
circumference were measured using a standardized
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Body weight of the participants wearing usual light
indoor clothing without shoes was measured with a 0.1
kg precision on a balanced beam scale (FINRISK, FIN-
D2D 2004) or on an electronic scale (FIN-D2D 2007).
BMI was calculated as weight (kg) divided by height
squared (m
2). Overweight and obesity were defined as BMI
25-29.9 kg/m
2 and ≥30 kg/m
2, respectively. Obesity was
further divided into class 1 (BMI 30-34.9), class 2 (BMI 35-
39.9), and class 3 (BMI ≥40) obesity [25]. Central obesity
was defined according to the IDF criteria [30]: waist cir-
cumference ≥94 cm in men, and ≥80 cm in women, and
according to the criteria used by WHO [31]: waist circum-
ference ≥102 cm in men, and ≥88 cm in women.
Statistical analysis was done by the SPSS program
v e r s i o n1 7( S P S S ,C h i g a g o ,I L ,U S A ) .T h eu n i v a r i a t e
ANOVA was used to test the difference in the continu-
ous variables and in the group-specific changes in them.
Logistic regression analysis was performed to evaluate
the differences in various prevalences between the study
areas. Interaction term ‘s t u d ya r e a×t i m ep o i n t ’ was
used to assess differences in changes between the areas.
Adjustment for age and gender was done, when appro-
priate. In the stratified analysis, genders and three age
groups (45-54, 55-64, and 65-74 years) were analysed
separately. Continuous variables are presented as mean
(standard deviation; SD) and categorical variables as
percentages.
The study protocols for FIN-D2D population survey
study as well as the FINRISK study were approved by
the Ethical Committee of the Hospital District of Hel-
sinki and Uusimaa. All the surveys were conducted
according to the ethical rules of the National Public
Health Institute, and the investigations were performed
in accordance with the Declaration of Helsinki. All par-
ticipants gave their written informed consent prior to
participation in the study.
Results
The overall response rate was 60% and 63% (beginning
and end, respectively) in the FIN-D2D area, and 49%
and 58% (beginning and end, respectively) in the control
area (Table 1). The mean age of the study participants
was higher at the end than at the beginning in both
study populations, due to the fact that the oldest age
group (65-74 years) was not included in the following
FINRISK-2002 study areas: Turku and Loimaa region,
Northern Savo, Northern Ostrobothnia and the Kainuu
area. No differences in age were seen between the FIN-
D2D and control areas at either time point (Table 1).
Changes in body weight and BMI
The mean body weight decreased significantly only in
men in the FIN-D2D area (from 85.6 ± 14.2 to 84.4 ±
14.3 kg, p=0.030) (Table 1). When stratified into age
groups, no significant changes were seen, although
Year 2007 2004 2002
Helsinki, 
Vantaa
Pirkanmaa
South 
Ostrobothnia
Northern 
Ostro-
bothnia
Turku, 
Loimaa
Northern 
Karelia
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FINRISK 2002
Northern Karelia
Kainuu
Turku-Loimaa
Helsinki-Vantaa
N=2038
Northern Savo
Northern 
Ostrobothnia 
N=917
FIN-D2D 2004
South Ostrobothnia
Central Finland
Pirkanmaa
N=2895
FIN-D2D 2007
South Ostrobothnia
Central Finland
Pirkanmaa
N=2862
FINRISK 2007
Northern Karelia
Kainuu
Turku-Loimaa
Helsinki-Vantaa
N=2250
Northern Savo 
Northern 
Ostrobothnia 
N=1294
Figure 1 Formation of the study population. The FIN-D2D area covers the hospital districts of South Ostrobothnia, Central Finland, Pirkanmaa,
Northern Ostrobothnia, and Northern Savo (light grey colour on the map and in the boxes), and the control area covers Northern Karelia,
Kainuu, Turku and Loimaa region, and the cities of Helsinki and Vantaa (dark grey colour on the map and in the boxes).
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groups in both genders. Among men, weight seemed to
decrease with increasing age. The mean BMI decreased
significantly only in men in the FIN-D2D area and
women in the control area (Table 1). When stratified
into age groups, BMI showed a decreasing trend in both
genders, areas, and all age groups across the studies, but
most so among the youngest men in the FIN-D2D area
(27.6 ± 4.2 vs. 27.0 ± 4.2 kg/m
2, p=0.015). Among
women, BMI increased with increasing age.
Changes in the prevalence of obesity
The prevalence of obesity was significantly lower in the
2007 survey among men in both study areas (Table 2).
Respectively, the prevalence of normal weight was
higher in the 2007 survey, especially among the young-
est age group in men. The prevalence of normal weight
was higher and the prevalence of overweight was lower
in the 2007 survey among women in the control area
(Table 3), whereas no changes among women in the
FIN-D2D area were observed. The prevalence of obesity
increased with increasing age among women (Table 3).
Altogether, normal weight was more prevalent among
women than among men (34.2% vs. 26.6%), whereas
overweight was more prevalent among men than among
women (49.8% vs. 37.8%) (Figure 2).
To examine these findings further, obesity was categor-
ized into subclasses 1, 2 and 3. The prevalence of class 1
obesity decreased in both areas, especially among men in
the youngest age group (Table 2). Class 3 (morbid) obe-
sity increased in the control area (from 1.2% to 2.3%, OR
1.97, 95% CI 1.21-3.22, p=0.007) and remained
unchanged in the FIN-D2D area (from 2.0% to 1.9%, p=
NS) (Figure 2). The intera c t i o nf o rs t u d ya r e a×t i m e
point was significant for the genders combined (p=
0.020), and for the women in the age group of 55-64
years (p=0.044). The prevalence of morbid obesity was
highest among 55-64 year old women in the control area
at the end of the study (4.0%, 95% CI 2.0%-5.8%), and
lowest among 65-74 year old men in the control area in
the beginning of the study (0.4%, 95% CI -0.4%-1.1%).
Altogether, class 2 and 3 obesity were more prevalent
among women than among men (6.7% vs. 4.0%, and 2.5%
vs. 1.2%, for classes 2 and 3, respectively) (Figure 2).
Changes in waist circumference and prevalence of central
obesity
Baseline waist circumference was larger in women in the
FIN-D2D area (89.2 ± 13.2 cm) than in the control area
(87.5 ± 12.6 cm) (p=0.001). The mean waist circumfer-
ence increased among women in the control area, but
remained unchanged in the FIN-D2D area (Table 1).
Table 1 Characteristics of the study participants according to sex, study area and timepoint
FIN-D2D area Control area
Beginning End Beginning End
Men
Number of subjects, invited 3175 3329 2060 1921
Participated (%) 1789 (56.3) 1982 (59.5) 984 (47.8) 1066 (55.5)
Age, years 59.1 (8.1) 60.1 (8.5)* 59.3 (7.8) 60.2 (8.2)*
Weight, kg 85.6 (14.2) 84.4 (14.3)* 85.1 (13.2) 84.5 (14.4)
BMI, kg/m
2 27.8 (4.1) 27.4 (4.2)* 27.9 (3.9) 27.6 (4.3)
Waist, cm 99.2 (11.6) 99.2 (11.8) 98.5 (11.1) 99.1 (12.1)
Women
Number of subjects, invited 3173 3319 2067 1931
Participated (%) 2023 (63.8) 2174 (65.5) 1054 (51.0) 1184 (61.3)
Age, years 58.5 (8.2) 59.3 (8.3)* 58.3 (7.8) 59.7 (8.4)*
Weight, kg 72.6 (13.7) 72.3 (14.2) 72.7 (13.7) 72.1 (14.2)
BMI, kg/m
2 27.7 (5.1) 27.6 (5.3) 28.0 (5.0) 27.6 (5.4)*
Waist, cm 89.2 (13.2) 89.7 (13.3) 87.5 (12.6) 89.4 (13.5)*
Total
Number of subjects, invited 6348 6648 4127 3852
Participated (%) 3812 (60.1) 4156 (62.5) 2038 (49.4) 2250 (58.4)
Age, years 58.8 (8.1) 59.7 (8.4)* 58.8 (7.8) 60.0 (8.3)*
Weight, kg 78.7 (15.4) 78.1 (15.5)* 78.7 (14.8) 78.0 (15.6)
BMI, kg/m
2 27.8 (4.7) 27.5 (4.8)* 27.9 (4.5) 27.6 (4.9)*
Waist, cm 93.9 (13.4) 94.3 (13.5) 92.8 (13.1) 94.0 (13.7)*
Data are presented as means (standard deviation) except where noted otherwise.
* p< 0.05 (adjusted for age) for the change from the beginning to the end of the study.
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both genders combined was also significant (p=0.040).
Among men, no significant changes in waist circumfer-
ence were seen in the control area or in the FIN-D2D
area (Table 1). Since the changes in the waist circumfer-
ence were rather modest, we saw no changes in the
prevalence of central obesity in either gender. Central
obesity was more prevalent in women than in men
(49.3% vs. 36.5%, and 74.5% to 66.8%, WHO and IDF
criteria, respectively). The prevalence of central obesity
increased with increasing age in both genders (Tables 2
and 3).
Table 2 Age-adjusted prevalence (95% confidence interval, CI) of normal weight, overweight, obesity and central
obesity in the beginning of the study and the changes in them in men according to the study area and age group
FIN-D2D area Control area
% (95% CI) Change (95% CI) p* % (95% CI) Change (95% CI) p* p**
45-54 years
Number of subjects 587 581 288 302
Normal weight 29.1 (25.4 - 32.8) 6.2 (0.8 - 11.5) .027 28.1 (22.9 - 33.3) 5.0 (-2.5 - 12.4) .185 .830
Overweight 47.5 (43.5 - 51.6) -1.1 (-6.8 - 4.7) .667 46.2 (40.4 - 52.0) 1.8 (-6.3 - 9.9) .769 .561
Obesity 23.3 (19.9 - 26.8) -5.1 (-9.8 - -0.4) .043 25.7 (20.6 - 30.8) -6.8 (-13.5 - -0.1) .066 .720
Class 1 obesity 18.1 (14.9 - 21.2) -4.8 (-9.0 - -0.6) .033 22.9 (18.0 - 27.8) -8.3 (-14.6 - -2.1) .014 .474
Class 2 obesity 3.6 (2.1 - 5.1) -0.1 (-2.3 - 2.0) .934 2.1 (0.4 - 3.7) 0.9 (-1.7 - 3.4) .453 .514
Class 3 obesity 1.7 (0.7 - 2.8) -0.2 (-1.6 - 1.3) .813 0.7 (-0.3 - 1.7) 0.6 (-1.0 - 2.3) .457 .447
Central obesity IDF 60.5 (56.5 - 64.4) -3.2 (-8.8 - 2.5) .310 56.6 (50.8 - 62.4) -1.0 (-9.0 - 7.1) .899 .659
Central obesity WHO 32.0 (28.2 - 35.8) -2.8 (-8.1 - 2.5) .379 29.9 (24.5 - 35.2) -3.4 (-10.7 - 3.9) .431 .862
55-64 years
Number of subjects 716 657 422 364
Normal weight 22.2 (19.2 - 25.3) 4.6 (0.0 - 9.1) .050 21.8 (17.8 - 25.8) 4.0 (-1.9 - 10.0) .174 .930
Overweight 52.0 (48.3 - 55.6) -0.5 (-5.8 - 4.8) .780 50.0 (45.2 - 54.8) -0.8 (-7.9 - 6.2) .782 .960
Obesity 25.8 (22.6 - 29.1) -4.1 (-8.6 - 0.4) .099 28.2 (23.9 - 32.5) -3.2 (-9.4 - 3.0) .320 .814
Class 1 obesity 19.7 (16.8 - 22.6) -3.9 (-7.9 - 0.2) .086 22.5 (18.5 - 26.5) -3.8 (-9.5 - 1.9) .191 .959
Class 2 obesity 4.9 (3.3 - 6.5) -0.9 (-3.1 - 1.3) .363 5.0 (2.9 - 7.1) -0.9 (-3.8 - 2.1) .569 .920
Class 3 obesity 1.3 (0.4 - 2.1) 0.7 (-0.6 - 2.1) .258 0.7 (-0.1 - 1.5) 1.5 (-0.2 - 3.1) .074 .414
Central obesity IDF 70.6 (67.3 - 74.0) -0.9 (-5.7 - 4.0) .749 67.5 (63.0 - 72.0) 4.1 (-2.4 - 10.6) .231 .251
Central obesity WHO 37.9 (34.3 - 41.5) 3.0 (-2.2 - 8.2) .217 37.9 (33.3 - 42.6) 2.6 (-4.3 - 9.4) .473 .863
65-74 years
Number of subjects 486 744 274 400
Normal weight 24.1 (20.3 - 27.9) 1.2 (-3.8 - 6.1) .588 21.9 (17.0 - 26.8) 4.1 (-2.5 - 10.7) .227 .489
Overweight 50.8 (46.4 - 55.3) 0.8 (-4.9 - 6.5) .828 49.3 (43.3 - 55.2) 2.5 (-5.2 - 10.2) .515 .726
Obesity 25.1 (21.2 - 29.0) -2.0 (-6.9 - 2.9) .422 28.8 (23.4 - 34.2) -6.6 (-13.2 - 0.1) .051 .291
Class 1 obesity 20.8 (17.2 - 24.4) -2.6 (-7.1 - 1.9) .276 23.7 (18.7 - 28.8) -7.0 (-13.1 - -0.9) .023 .273
Class 2 obesity 3.3 (1.7 - 4.9) 1.1 (-1.1 - 3.4) .370 4.7 (2.2 - 7.3) 0.0 (-3.3 - 3.3) .969 .529
Class 3 obesity 1.0 (0.1 - 1.9) -0.5 (-1.5 - 0.5) .297 0.4 (-0.4 - 1.1) 0.4 (-0.8 - 1.6) .538 .296
Central obesity IDF 74.1 (70.2 - 78.0) -2.1 (-7.2 - 3.0) .385 69.3 (63.8 - 74.8) -0.5 (-7.6 - 6.6) .887 .690
Central obesity WHO 39.9 (35.5 - 44.3) 0.1 (-5.5 - 5.7) .976 38.3 (32.5 - 44.1) 1.4 (-6.2 - 8.9) .730 .787
Total
Number of subjects 1789 1982 984 1066
Normal weight 25.0 (23.0 - 27.0) 4.1 (1.2 - 6.9) .005 23.7 (21.0 - 26.3) 4.6 (0.8 - 8.4) .018 .791
Overweight 50.2 (47.9 - 52.5) -0.3 (-3.5 - 2.9) .866 48.7 (45.6 - 51.8) 1.0 (-3.3 - 5.3) .654 .640
Obesity 24.8 (22.8 - 26.8) -3.8 (-6.5 - -1.1) .006 27.6 (24.8 - 30.4) -5.6 (-9.3 - -1.8) .004 .496
Class 1 obesity 19.5 (17.6 - 21.3) -3.8 (-6.2 - -1.3) .003 23.0 (20.3 - 25.6) -6.3 (-9.7 - -2.8) .000 .291
Class 2 obesity 4.0 (3.1 - 4.9) 0.0 (-1.3 - 1.2) .949 4.1 (2.8 - 5.3) -0.1 (-1.9 - 1.6) .867 .994
Class 3 obesity 1.3 (0.8 - 1.9) 0.0 (-0.7 - 0.7) .976 0.6 (0.1 - 1.1) 0.8 (0.0 - 1.7) .063 .124
Central obesity IDF 68.2 (66.1 - 70.4) -1.9 (-4.9 - 1.0) .204 64.8 (61.8 - 67.8) 0.6 (-3.5 - 4.7) .776 .325
Central obesity WHO 36.5 (34.3 - 38.8) 0.2 (-2.9 - 3.2) .919 35.7 (32.7 - 38.7) 0.0 (-4.1 - 4.2) .986 .982
*p-value for change, adjusted for age.
**Interaction for study area × timepoint, adjusted for age.
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The Finnish Programme for the Prevention of Type 2
Diabetes [22] is the first large-scale national programme
ever launched to combat the diabetes epidemic at the
population-level. The implementation project of this
program, FIN-D2D, focused mainly on the high-risk
strategy, and the strategy of early diagnosis and treat-
ment [25]. The FIN-D2D also supported the population
strategy and it gained a lot of publicity in the whole
country because its main aim was to restrain the obesity
epidemic by means of nutritional interventions and
increased physical activity. As shown in the present
Table 3 Age-adjusted prevalence (95% confidence interval, CI) of normal weight, overweight, obesity and central
obesity in the beginning of the study and the changes in them in women according to the study area and age group
FIN-D2D area Control area
% (95% CI) Change (95% CI) p* % (95% CI) Change (95% CI) p* p**
45-54 years
Number of subjects 725 713 369 358
Normal weight 41.5 (37.9 - 45.1) 2.1 (-3.0 - 7.2) .489 40.1 (35.1 - 45.1) 7.4 (0.2 - 14.6) .067 .270
Overweight 35.2 (31.7 - 38.7) -1.4 (-6.3 - 3.5) .662 37.4 (32.4 - 42.4) -7.0 (-13.8 - -0.1) .062 .212
Obesity 23.3 (20.2 - 26.4) -0.7 (-5.1 - 3.6) .750 22.5 (18.2 - 26.8) -0.4 (-6.5 - 5.6) .958 .928
Class 1 obesity 16.4 (13.7 - 19.1) -1.0 (-4.8 - 2.8) .615 13.3 (9.8 - 16.8) 0.7 (-4.3 - 5.7) .764 .607
Class 2 obesity 5.4 (3.7 - 7.0) -0.5 (-2.8 - 1.8) .694 7.6 (4.9 - 10.3) -2.8 (-6.3 - 0.7) .114 .312
Class 3 obesity 1.5 (0.6 - 2.4) 0.7 (-0.7 - 2.1) .314 1.6 (0.3 - 2.9) 1.7 (-0.5 - 4.0) .100 .581
Central obesity IDF 68.0 (64.6 - 71.4) 0.7 (-4.1 - 5.5) .709 62.8 (57.8 - 67.7) 2.8 (-4.2 - 9.8) .348 .602
Central obesity WHO 42.0 (38.4 - 45.6) 2.4 (-2.7 - 7.6) .304 34.5 (29.6 - 39.4) 4.1 (-2.9 - 11.2) .210 .641
55-64 years
Number of subjects 812 746 436 407
Normal weight 30.5 (27.4 - 33.7) 3.8 (-0.9 - 8.4) .121 28.9 (24.6 - 33.2) 6.2 (-0.1 - 12.5) .052 .513
Overweight 39.9 (36.5 - 43.3) -0.9 (-5.8 - 4.0) .734 40.4 (35.7 - 45.0) -4.0 (-10.6 - 2.6) .240 .454
Obesity 29.6 (26.4 - 32.7) -2.9 (-7.4 - 1.6) .214 30.7 (26.4 - 35.1) -2.2 (-8.4 - 4.0) .463 .876
Class 1 obesity 18.6 (15.9 - 21.3) -1.3 (-5.1 - 2.5) .509 20.9 (17.0 - 24.7) -3.4 (-8.8 - 1.9) .199 .530
Class 2 obesity 7.8 (5.9 - 9.6) -0.5 (-3.1 - 2.1) .722 7.8 (5.3 - 10.3) -0.7 (-4.2 - 2.9) .715 .933
Class 3 obesity 3.2 (2.0 - 4.4) -1.1 (-2.7 - 0.6) .192 2.1 (0.7 - 3.4) 1.9 (-0.4 - 4.2) .116 .044
Central obesity IDF 76.5 (73.6 - 79.4) 2.9 (-1.3 - 7.0) .166 73.3 (69.2 - 77.5) 2.1 (-3.8 - 8.0) .496 .757
Central obesity WHO 52.7 (49.3 - 56.2) -1.8 (-6.8 - 3.1) .478 48.0 (43.3 - 52.8) 2.3 (-4.5 - 9.1) .503 .337
65-74 years
Number of subjects 486 715 249 419
Normal weight 26.3 (22.4 - 30.3) 0.7 (-4.5 - 5.8) .773 22.5 (17.3 - 27.7) 6.6 (-0.3 - 13.6) .066 .163
Overweight 40.9 (36.6 - 45.3) -0.8 (-6.5 - 4.9) .665 41.4 (35.2 - 47.5) -2.7 (-10.4 - 5.0) .484 .744
Obesity 32.7 (28.5 - 36.9) 0.2 (-5.3 - 5.6) .857 36.1 (30.1 - 42.2) -3.9 (-11.4 - 3.5) .319 .341
Class 1 obesity 23.0 (19.3 - 26.8) 0.0 (-4.8 - 4.9) .880 26.1 (20.6 - 31.6) -2.7 (-9.5 - 4.0) .455 .463
Class 2 obesity 6.8 (4.5 - 9.0) 0.1 (-2.8 - 3.0) .970 8.8 (5.3 - 12.4) -1.9 (-6.1 - 2.3) .375 .471
Class 3 obesity 2.9 (1.4 - 4.4) 0.1 (-1.9 - 2.0) .854 1.2 (-0.2 - 2.6) 0.7 (-1.3 - 2.7) .502 .573
Central obesity IDF 81.1 (77.6 - 84.6) -0.8 (-5.4 - 3.7) .808 77.5 (72.3 - 82.7) 5.1 (-1.1 - 11.3) .099 .162
Central obesity WHO 58.8 (54.5 - 63.2) -2.7 (-8.4 - 3.0) .492 54.2 (48.0 - 60.4) 2.6 (-5.2 - 10.4) .492 .341
Total
Number of subjects 2023 2174 1054 1184
Normal weight 33.5 (31.4 - 35.5) 2.1 (-0.7 - 5.0) .147 31.3 (28.5 - 34.1) 6.7 (2.8 - 10.6) .001 .071
Overweight 38.5 (36.3 - 40.6) -1.0 (-4.0 - 1.9) .491 39.6 (36.6 - 42.5) -4.6 (-8.6 - -0.5) .026 .155
Obesity 28.1 (26.1 - 30.0) -1.1 (-3.8 - 1.6) .436 29.1 (26.4 - 31.9) -2.1 (-5.9 - 1.6) .261 .703
Class 1 obesity 18.9 (17.2 - 20.6) -0.6 (-2.9 - 1.8) .642 19.4 (17.1 - 21.8) -1.8 (-5.0 - 1.5) .289 .645
Class 2 obesity 6.7 (5.6 - 7.8) -0.4 (-1.9 - 1.1) .604 8.0 (6.3 - 9.6) -1.7 (-3.9 - 0.4) .110 .326
Class 3 obesity 2.5 (1.8 - 3.2) -0.1 (-1.1 - 0.8) .805 1.7 (0.9 - 2.5) 1.4 (0.1 - 2.6) .038 .080
Central obesity IDF 74.6 (72.7 - 76.5) 1.1 (-1.5 - 3.7) .398 70.6 (67.9 - 73.4) 3.2 (-0.5 - 6.8) .090 .342
Central obesity WHO 50.3 (48.2 - 52.5) -0.4 (-3.4 - 2.6) .802 44.8 (41.8 - 47.8) 3.0 (-1.1 - 7.1) .149 .157
*p-value for change, adjusted for age.
**Interaction for study area × timepoint, adjusted for age.
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Page 6 of 10study, this goal was achieved, since the mean body
weight, mean BMI, and the prevalence of obesity
decreased, whereas the prevalence of normal weight
increased. This suggests that the prevalence of obesity
may be decreasing among 45-74 year old Finns. To our
knowledge, this is the first report to show a decline in
the prevalence of obesity at the population-level, both in
the FIN-D2D and the control area. Interestingly, the
waist circumference increased in the control area,
whereas it remained unchanged in the FIN-D2D area.
However, the increase in waist circumference in the
control area was more modest than reported earlier for
years 1987-2002 [32], and the prevalence of central obe-
sity did not increase significantly in either area.
There is large geographic variation in the prevalence of
obesity among European countries, with central, eastern,
and southern regions showing higher rates than the wes-
tern and northern (including Finland) regions [33]. Studies
from Spain, Canada, Denmark, Portugal, and South
Australia [34-38] have shown that the prevalence of obe-
sity has increased between the mid-1990s and the begin-
ning of the 2000s. In Finland, national FINRISK studies
have shown that the increase in BMI has slowed down in
men, and has been quite stable in women between 1997
and 2002, whereas a remarkable shift towards higher waist
circumference has been observed [32]. BMI did not
increase significantly between 1997 and 2002 in the age
groups of 35-64 years, but it increased significantly in the
youngest age group, 25-34 years, where also the increase
in waist circumference was greatest [32]. Among US
adults the increases in the prevalence of obesity previously
observed does not appear to be continuing at the same
rate during the past 10 years, particularly for women [3].
In Sweden, the increase in the prevalence of obesity has
levelled off during 2000-2005 [39] compared to the 10%
increase seen during the years 1996-2001 [40]. In our
study, a significant decrease in the prevalence of obesity at
the population-level was seen for the first time.
In addition to the changes seen in the FIN-D2D area,
most changes in body weight and the prevalence of obesity
were similar in the control area, especially among men.
Although the five hospital districts of FIN-D2D formed a
pilot area, the information of the importance of healthy
lifestyles in the prevention of diabetes had also spread out-
side the FIN-D2D area, which was the aim of population
strategy, as well. Moreover, the control area is part of the
FINRISK area, where the measurements of cardiovascular
risk factors have been repeated every five years since 1972
with impressing results [27,28], and they have also
received feedback of these results. Therefore, the control
area can be considered better as a mini-intervention area
rather than a pure control area. The latest FINRISK-survey
showed that many cardiovascular risk factors were pro-
ceeding into the right direction among 25-64 year old
individuals in Finland [4,41]. However, the use of alcohol
was still high [42], and this could be a reason why the
waist circumference was increasing [32], and why the ben-
eficial trend in blood pressure had now levelled off [4].
There were also substantial differences among the stu-
died areas on how they succeeded in the project, which
can largely be explained by their different ways of action
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Figure 2 Categories of BMI. Changes in the prevalence of normal
weight (BMI < 25 kg/m
2), overweight (BMI 25-29.9 kg/m
2), obesity
class 1 (BMI 30-34.9 kg/m
2), class 2 (BMI 35-39.9 kg/m
2), and class 3
(BMI ≥40 kg/m
2) are shown by sex and study area. Significant (p
<0.05) age-adjusted changes and interactions for study area × time
point are marked (⋆)
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Page 7 of 10in the prevention of chronic diseases, and also their dif-
ferent population structures. It should also be noted
that the prevalence of diabetes in the FIN-D2D area has
already for a long time been higher than the mean pre-
valence of diabetes in Finland [25]. The areas were thus
establishing this project from different starting points,
but they also reached the goals differently. The FIN-
D2D was a national health promoting programme, and
not an actual scientific study. However, from the very
beginning it was decided to analyse its influence by
comparing changes in adiposity markers in the FIN-
D2D area and the preselected control area.
In this study based on the two cross-sectional surveys
with 3 to 5 years of follow-up it was surprising that men
in the FIN-D2D area (especially the youngest age group)
were able to reduce their body weight more than women.
Usually women are more likely to participate in lifestyle
change programmes than men [43]. In FIN-D2D there
were several projects focusing on men especially, which
may have encouraged men to join these projects, and to
also succeed in them. The threshold for men to participate
is usually higher than that for women, but their commit-
ment nevertheless is usually better [43-45]. Also, the inter-
ventions aimed at women may indirectly affect also men
due to the fact that men usually eat meals prepared by
women [46]. Women in the control area showed beneficial
changes in the prevalence of normal weight and over-
weight, but on the other hand, adverse changes regarding
waist circumference and the prevalence of morbid obesity.
Of course, one could speculate, whether the result con-
cerning morbid obesity is a real finding or just a statistical
coincidence. However, both FIN-D2D and the control
population are selected as random independent samples of
individuals, specified by region, gender, and age group,
being thus a representative sample of the population. Simi-
lar changes in the prevalence of morbid obesity were
observed in all sub-regions, i.e. the prevalence of morbid
obesity increased in all sub-regions of the control area,
and remained unchanged, in all FIN-D2D hospital
districts.
The prevalence of severe (BMI ≥35 kg/m
2) and morbid
(BMI ≥40 kg/m
2) obesity has increased in Finland 2.7-fold
and 5.6-fold, respectively, during 1978-2001 [47].
Although the number of massively obese individuals is still
rather low in Finland, it would be of importance to
restrain their number from increasing further. In USA the
prevalence of morbid obesity is 5.4% in the age group of
40 or older [3], which is nearly three times the prevalence
in Finland (1.9% with FIN-D2D and FINRISK studies com-
bined). Although rather rare, this extreme group of people
incur huge expenses along with increasing surgical treat-
ment of obesity.
The present results indicate that the obesity epidemic
might be stabilizing or even decreasing in Finland. If
this trend is sustainable, also the incidence of type 2 dia-
betes might follow the obesity trends, and ease off dur-
ing the years to come. To achieve this goal, we must
now be able to maintain and to continue the progres-
sion already made regarding body weight. Furthermore,
it would also be very important to be able to spread
healthier lifestyles into the younger age groups, since
obesity appears to reduce life expectancy markedly,
especially among younger adults [48].
Limitations of the study
There were some differences in the age group distribu-
tion, since the oldest age group was not included in cer-
tain baseline study areas. However, since Turku-Loimaa
and Kainuu belong to the control area, and Northern
Savo and Northern Ostrobothnia belong to the FIN-D2D
area, the age group distribution remains similar between
the study groups. These areas represent 39% of the con-
trol area population, and 31% of the FIN-D2D area popu-
lation in the follow-up. In all statistical analysis, age was
included as a cofactor. The participation rates were
rather low, especially in the control area. We do not
know the reason for this. Moreover, there were some dif-
ferences between the areas concerning certain back-
ground factors. Larger urban areas were not evenly
distributed between the FIN-D2D and the control area,
with the control area including for example the big cities
of Helsinki and Turku. Individuals in the FIN-D2D area
had slightly shorter duration of education and their cigar-
ette smoking was somewhat less frequent than in the
control area, whereas no difference in leisure-time physi-
cal activity was seen. When these factors were taken into
account, the observed interactions for study area × time
point were still significantf o rw a i s tc i r c u m f e r e n c e( p =
0.013) and morbid obesity (p = 0.028), when both gen-
ders were combined. Furthermore, the interaction con-
cerning waist circumference among women became
significant with these adjustments (p = 0.014), whereas it
was not significant without these adjustments (p =
0.062). Adding the variable of sub-region into the statisti-
cal models had no effect, and was thus left out. Thus, we
can conclude that the differences between the areas were
not due to these background factors.
Conclusions
In conclusion, the overall body weight and the preva-
lence of obesity have been decreasing among Finns aged
45 to 74 years, both at the FIN-D2D and the control
area. The significant differences in the prevalence of
morbid obesity and mean waist circumference observed
between the FIN-D2D area and control area suggest
that the implementation of a national diabetes preven-
tion programme may have been successful in the five
hospital districts where this programme was established.
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Page 8 of 10However, since most of the findings were not signifi-
c a n t ,w ec a nn o tb ec e r t a i no ft h et r u ee x t e n to ft h e
change, and future surveys may give additional data on
the direction of this trend in Finland.
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